281TiPA phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE). (23rd October 2018) - Devaux, A; Canon, J-L; Duhoux, F P; Delrée, P; Galant, C; Coulie, P G; Bar, I; Constant, M; Haussy, S; Bricard, O; Missault, K; Berlière, M; et al.